ASRT Logo

Assertio Holdings, Inc. (ASRT) 

NASDAQ
Market Cap
$84.58M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
292 of 960
Rank in Industry
13 of 59

Largest Insider Buys in Sector

ASRT Stock Price History Chart

ASRT Stock Performance

About Assertio Holdings, Inc.

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, …

Insider Activity of Assertio Holdings, Inc.

Over the last 12 months, insiders at Assertio Holdings, Inc. have bought $105,300 and sold $11,463 worth of Assertio Holdings, Inc. stock.

On average, over the past 5 years, insiders at Assertio Holdings, Inc. have bought $104,412 and sold $2.16M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Mason Heather L (Interim Executive Officer) — $168,500. O'Grady Brendan P. (CEO) — $19,901. Vacirca Jeff L (director) — $11,100.

The last purchase of 75,000 shares for transaction amount of $60,000 was made by Mason Heather L (director) on 2024‑11‑18.

List of Insider Buy and Sell Transactions, Assertio Holdings, Inc.

2024-11-18Purchasedirector
75,000
0.0747%
$0.80$60,000+20.30%
2024-11-14PurchaseCEO
11,706.46
0.0124%
$0.85$9,950-4.54%
2024-06-11Purchasedirector
10,000
0.0108%
$1.11$11,100+4.63%
2024-06-05PurchaseInterim Executive Officer
25,000
0.0255%
$0.97$24,250+12.03%
2024-03-14Saledirector
10,251
0.0106%
$1.12$11,463-4.55%
2023-09-12SalePresident & CEO
31,121
0.0334%
$2.97$92,432-63.97%
2023-09-11SalePresident & CEO
127,281
0.1363%
$3.04$386,972-64.92%
2023-09-11SaleSVP and CAO
64,313
0.0689%
$3.04$195,795-64.92%
2023-09-11SaleSVP, General Counsel
45,236
0.0484%
$3.04$137,441-64.92%
2023-09-11SaleSVP and CFO
104,980
0.1136%
$3.07$322,593-64.92%
2023-08-14Saledirector
22,000
0.0385%
$3.14$69,045-66.23%
2023-05-19Saledirector
89,286
0.1751%
$7.30$652,011-83.70%
2023-05-05Saledirector
43,143
0.0825%
$6.00$258,767-65.37%
2022-05-12Sale
22,322
0.0431%
$2.35$52,488+31.56%
2022-05-12Sale
44,643
0.0864%
$2.36$105,170+31.56%
2022-04-11SalePresident and CEO
26,391
0.0628%
$3.50$92,369-2.52%
2022-04-05SalePresident and CEO
34,518
0.0829%
$3.50$120,813-1.59%
2021-05-20PurchasePresident and CEO
31,818
0.0736%
$1.54$49,000+9.40%
2021-05-20PurchaseSVP and CFO
19,500
0.0443%
$1.51$29,523+9.40%
2021-05-20PurchaseSVP and CAO
16,339.87
0.0375%
$1.53$25,000+9.40%

Insider Historical Profitability

9.4%
Mason Heather Ldirector
287650
0.3013%
$0.8921
Vacirca Jeff Ldirector
151159
0.1583%
$0.8910
O'Grady Brendan P.CEO
11706
0.0123%
$0.8910
Peisert Daniel A.President & CEO
324939
0.3403%
$0.8914+9.4%
Patel AjaySVP and CAO
93643
0.0981%
$0.8911+9.4%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Nantahala Capital Management Llc$8.89M9.759.27M+21.67%+$1.58M0.41
BlackRock$6.09M6.686.35M-3.4%-$214,335.40<0.0001
The Vanguard Group$4.72M5.174.92M+0.84%+$39,399.41<0.0001
AQR Capital$3.1M3.43.23M+61.74%+$1.18M0.01
Russell Investments Group Ltd$2.25M2.472.35M+22,096.18%+$2.24M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.